A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)
收藏DataCite Commons2024-12-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007647/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Primary Objective:
To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination
(FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 30.
Secondary Objective:
To compare the overall efficacy and safety of insulin glargine/lixisenatide FRC to insulin
glargine (with or without metformin) over a 30 week treatment period in participants with
type 2 diabetes.
提供机构：
Vivli
创建时间：
2022-02-02
